Trial
NCT04963413
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Florida
Collaborators
Immunomic Therapeutics, Inc.
Condition
Glioblastoma
Intervention
Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Why stopped
Terminated by mutual agreement by sponsor and institution.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-06